

Seed Innovations Ltd / AIM: SEED / Sector: Closed End Investments

30 April 2025

**SEED Innovations Limited**  
("SEED" or the "Company")

**Investee Company Update: Little Green Pharma Ltd**

*Robust double-digit year-on-year growth*

SEED Innovations Ltd, the AIM-quoted investment company offering exposure to disruptive, high-growth, life sciences and technology ventures typically inaccessible to everyday investors, is pleased to note that its portfolio company, Little Green Pharma Ltd ('LGP'), has published its quarterly activities report and Appendix 4C for the period ending 31 March 2025 on the ASX.

The Company owns 7,324,796 ordinary shares in LGP representing 2.43% of LGP's issued share capital.

**Commenting on the announcement, Ed McDermott, SEED CEO, said:** *"LGP continues to deliver strong double-digit year-on-year growth, with cash receipts surpassing A 10 million in the quarter ended 31 March 2025. The company remains in a solid financial position, with net tangible assets significantly outweighing its enterprise value and minimal long-term debt. Increasing sales momentum in Germany and the UK further reinforces LGP's strategic direction, and we remain confident in the company's ability to sustain this positive trajectory."*

The following excerpt from the announcement, which was released on the ASX, is set out without any material changes.

**Little Green Pharma Ltd**

**Quarterly Activities Report and Appendix 4C**

Little Green Pharma Ltd (ASX: LGP, "LGP" or the "Company") is pleased to provide its activities report and Appendix 4C for the quarter ending 31 March 2025.

**Highlights**

- LGP FY25 revenue of 36.6 million (unaudited) representing over 40% growth from prior year, with Health House generating further 0.8 million in third party product sales in two months post-acquisition
- LGP revenue of 9.6 million (unaudited) for quarter, up over 30% from prior corresponding period with record March month of 4.0 million (unaudited)
- Cash receipts including Health House of 10.3 million up nearly 30% from prior corresponding period
- Successful acquisition and integration of Health House distribution business
- NAB loan facilities extended to 30 June 2027
- French national cannabis legislation submitted to European Commission; commercial access expected late CY25 / early CY26
- 12-month QUEST results released and published in PLOS One journal with results showing long-term efficacy of LGP medicinal cannabis for various chronic conditions
- Department of Veterans Affairs confirmed funding of MDMA and Psilocybin assisted therapies for veterans with post-traumatic stress disorder and treatment resistant depression
- Strengthening of board with appointment of Mr Paul Long as Managing Director and Mr David Fenlon as an Independent Non Executive Director
- Cash in bank of 2.4 million

The announcement in full can be accessed from the following link:  
<https://www.investlittlegreenpharma.com/site/showdownloaddoc.aspx?AnnounceGuid=715a80ae-ca84-4a24-9aff-d8791e2321c4>

*This announcement contains inside information for the purposes of Article 7 of EU Regulation No. 596/2014, which forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 (as amended).*

**- Ends -**

For further information on the Company please visit: [www.seedinnovations.co](http://www.seedinnovations.co) or contact:

Ed McDermott	SEED Innovations Ltd	E: <a href="mailto:info@seedinnovations.co">info@seedinnovations.co</a>
Lance de Jersey		

James Biddle	Beaumont Cornish Limited,	T: (0)20 7628 3396
Roland Cornish	Nomad	

Isabella Pierre	Shard Capital Partners LLP	T: (0)20 7186 9927
Damon Heath	Broker	

Ana Ribeiro	St Brides Partners Ltd,	E: <a href="mailto:seed@stbridespartners.co.uk">seed@stbridespartners.co.uk</a>
Isabel de Salis	Financial PR	

## **NOTES**

### **Seed Innovations Ltd**

Seed Innovations Ltd is an AIM quoted investment company offering exposure to disruptive, high-growth, life sciences and technology ventures typically inaccessible to everyday investors. Its strategy focuses on identifying early-stage opportunities with upcoming investment catalysts, alongside more mature investments providing near-term liquidity. With a portfolio of such investments and cash reserves, the Company is agile and poised to capitalise swiftly on new investment opportunities.

### **Nominated Adviser**

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

PFUEAFLEDENSEFA